

Resource Summary Report

Generated by [RRID](#) on Aug 26, 2026

pLenti CMV GFP Hygro (656-4)

RRID:Addgene_17446

Type: Plasmid

Proper Citation

RRID:Addgene_17446

Plasmid Information

URL: <http://www.addgene.org/17446>

Proper Citation: RRID:Addgene_17446

Insert Name: GFP

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:19657394](#)

Vector Backbone Description: Backbone Size:8591; Vector Backbone:p156RRL-sinPPT-CMV-GFP-PRE/Nhe I; Vector Types:Mammalian Expression, Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: pLenti CMV GFP Hygro (656-4)

Record Creation Time: 20220422T222008+0000

Record Last Update: 20260815T081040+0000

Ratings and Alerts

No rating or validation information has been found for pLenti CMV GFP Hygro (656-4).

No alerts have been found for pLenti CMV GFP Hygro (656-4).

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 61 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tsuji T, et al. (2026) Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells. *Cancer research*, 86(6), 1414.

Becker AP, et al. (2026) Photosensitizer proximity labeling captures the lipid and protein interactomes. *Nature chemical biology*.

Lee JH, et al. (2026) N6-adenosine methylation enhances nuclear mRNA export through METTL3 and NUP93. *Nature cell biology*, 28(3), 553.

Li S, et al. (2026) Lung mucosal and systemic responses at single-cell resolution in an aerosolized *Mycobacterium bovis* BCG human challenge model. *Cell reports. Medicine*, 7(6), 102830.

Boyack I, et al. (2025) A Potential Role for c-MYC in the Regulation of Meibocyte Cell Stress. *Cells*, 14(10).

Baldacci S, et al. (2025) Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy. *Cancer discovery*.

Obuchi W, et al. (2025) Engineering of CD63 Enables Selective Extracellular Vesicle Cargo Loading and Enhanced Payload Delivery. *Journal of extracellular vesicles*, 14(6), e70094.

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. *Cell stem cell*, 32(3), 463.

Niceforo A, et al. (2025) Analysis of astrocyte progenitors derived from human induced pluripotent stem cells in vitro and following transplantation into the intact spinal cord. *bioRxiv : the preprint server for biology*.

Hu X, et al. (2025) The transcription factor MEF2C restrains microglial overactivation by inhibiting kinase CDK2. *Immunity*, 58(4), 946.

Wang X, et al. (2025) PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. *Cancer discovery*, 15(3), 633.

Chau LF, et al. (2025) Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease. *Nature communications*, 16(1), 766.

Brea EJ, et al. (2025) Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. *Cancer immunology research*, 13(11), 1749.

Hwang SP, et al. (2025) TRMT1L-catalyzed m22G27 on tyrosine tRNA is required for efficient mRNA translation and cell survival under oxidative stress. *Cell reports*, 44(1), 115167.

Youn D, et al. (2025) Cross-talks between Metabolic and Translational Controls during Beige Adipocyte Differentiation. *Nature communications*, 16(1), 3373.

Carstens EJ, et al. (2025) Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies. *Nature communications*, 16(1), 9651.

Palma FR, et al. (2024) Histone H3.1 is a chromatin-embedded redox sensor triggered by tumor cells developing adaptive phenotypic plasticity and multidrug resistance. *Cell reports*, 43(3), 113897.

Acosta Montaña P, et al. (2024) Development of Liver-Targeting α -V β 5+ Exosomes as Anti-TGF- β Nanocarriers for the Treatment of the Pre-Metastatic Niche. *Biology*, 13(12).

Klomp JE, et al. (2024) Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. *Science (New York, N.Y.)*, 384(6700), eadk0850.

Ma J, et al. (2024) Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression. *Scientific reports*, 14(1), 14914.